To test the therapeutic effect of the peptide in vivo, the 8R10Q peptide was delivered through intranasal aspiration 6 days/week into the wild‐type (WT) or R6/2 transgenic mice, the HD animal model expressing Htt exon 1 with an increased CAG repeat expansion, when they were 4 weeks of age. This evidence concerns the gene HTT and Huntington disease.